ES2140336A1 - Non-virulent mutants of Brucella abortus. - Google Patents

Non-virulent mutants of Brucella abortus.

Info

Publication number
ES2140336A1
ES2140336A1 ES009800043A ES9800043A ES2140336A1 ES 2140336 A1 ES2140336 A1 ES 2140336A1 ES 009800043 A ES009800043 A ES 009800043A ES 9800043 A ES9800043 A ES 9800043A ES 2140336 A1 ES2140336 A1 ES 2140336A1
Authority
ES
Spain
Prior art keywords
mutants
brucella abortus
bvrr
brucella
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009800043A
Other languages
Spanish (es)
Other versions
ES2140336B1 (en
Inventor
Goni Ignacio Lopez
Alberto Sola-Landa
Garcia Ramon Diaz
Uria Ignacio Moriyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES9800043A priority Critical patent/ES2140336B1/en
Publication of ES2140336A1 publication Critical patent/ES2140336A1/en
Application granted granted Critical
Publication of ES2140336B1 publication Critical patent/ES2140336B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Non-virulent mutants of Brucella abortus. A description is given of stable point mutants obtained by insertion of the transposon Tn5 in the genes of Brucella abortus bvrR and bvrS, a two-component transduction-regulating system. The mutants are selected for their sensitivity to bactericidal cationic peptides and surface-active agents. Said peptides keep the smooth characteristics of their lipopolysaccharide, but are totally avirulent in the murine model. Mutant strains of Brucella abortus are obtained, specifically the strain 2.13 (NCTC 13091) with an insertion in the gene bvrR and the strain 65.21 (NCTC 13092) with an insertion in the gene bvrR, both mutants derived from the virulent parental strain Brucella abortus 2308. The natural host of Brucella abortus is cattle, although it can also infect other types of livestock and even man. These mutants can therefore be used as vaccines against brucellosis both in humans and in animals. Moreover, because of the adjuvant capacity of Brucella they can also be used as antigen-presenting recombinant vaccines.
ES9800043A 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS. Expired - Lifetime ES2140336B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9800043A ES2140336B1 (en) 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9800043A ES2140336B1 (en) 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Publications (2)

Publication Number Publication Date
ES2140336A1 true ES2140336A1 (en) 2000-02-16
ES2140336B1 ES2140336B1 (en) 2000-10-16

Family

ID=8302367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9800043A Expired - Lifetime ES2140336B1 (en) 1998-01-13 1998-01-13 NON-VIRULENT MUTANTS OF BRUCELLA ABORTUS.

Country Status (1)

Country Link
ES (1) ES2140336B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016728A1 (en) * 1992-02-25 1993-09-02 The Texas A & M University System Improved vaccin against brucella abortus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016728A1 (en) * 1992-02-25 1993-09-02 The Texas A & M University System Improved vaccin against brucella abortus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHARLES T.C. et al. "A chromosomally encoded two-component sensory transduction system is required for virulence of Agrobacterium tumefacieus". 1993. J. Bacteriol. Vol. 175 (20). Paginas 6614-6625. *
MOREIRA JACOB. "In vitro species (or type) transformation among strains of Brucella". 1963. Nature. Vol. 197. Pagina 406. *
MORENO et al. "Immunochemical characterization of Brucella lipopolysaccharides and polysaccharides". 1981. Infect. Immun. Vol. 31. Paginas 214-222. *
MORENO et al. "Purification and characterizacion of smooth and rough lipopolysaccharides from Brucella abortus". 1979. J. Bacteriol. Vol. 138. Paginas 361-369. *
PRICE et al. "Survival of smooth, rough and transposon mutant strains of Brucella abortus in bovine mammary macrophages". 1990. Vet. Immunol. Immunopath. Vol. 26 (4). Paginas 353-366. *
SANGARI et al. "Mutagenesis of Brucella abortus: Comparative efficiency of three transposon delivery systems". 1991. Vol. 11. Paginas 443-446. *
SMITH et al. "Transposon Tn5 mutagenesis of Brucella abortus". 1987. Infection and Immunity. Vol. 55. Paginas 2774-2776. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis

Also Published As

Publication number Publication date
ES2140336B1 (en) 2000-10-16

Similar Documents

Publication Publication Date Title
Heithoff et al. Salmonella DNA adenine methylase mutants confer cross-protective immunity
Marchetti et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant
Ugalde et al. Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine
IL141623A0 (en) Method of dna vaccination
HUT70986A (en) Vaccines against aujeszky`s disease and other animal diseases containing pseudorabies virus mutants
ITFI920052A1 (en) PROTEIN EXTRACTED FROM HELICOBACTER PYLORI CYTOTOXIC STRAINS, GENE THAT EXPRESSES IT, USE OF PROTEIN AS VACCINE OR DIAGNOSTIC.
WO1996015241A3 (en) A polynucleotide tuberculosis vaccine
PL344593A1 (en) Attenuated mutants of salmonella
DE69333028D1 (en) DELETION MUTANTS AS VACCINES AGAINST CHOLERA
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
Baron et al. Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a
PL343246A1 (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
Fuller et al. A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine
TR200002974T2 (en) Live vaccine against brucellosis
ES2140336A1 (en) Non-virulent mutants of Brucella abortus.
Temprano et al. Potential use of a Yersinia ruckeri O1 auxotrophic aroA mutant as a live attenuated vaccine
DE69333751D1 (en) NON-DISTRIBUTING LIVING HERPESVIRUSVAKZIN
Bloom New approaches to vaccine development
AP9901666A0 (en) Leishmania vaccine.
Saito et al. Complement-Mediated Killing ofPorphyromonas gingivalis381 by the Immunoglobulin G Induced by Recombinant 40-kDa Outer Membrane Protein
BR0013093A (en) Streptomyces avermitilis gene that regulates the ratio of avermectins b2: b1
FR2809960B1 (en) ADJUVANT COMPOSITION OF THE IMMUNE RESPONSE COMPRISING FHA PROTEIN OR A FRAGMENT OF FHA PROTEIN IN FREE FORM, AND IMMUNOGENIC OR VACCINE COMPOSITION CONTAINING SUCH ADJUVANT COMPOSITION
RU97118243A (en) VACCINE AGAINST BRAZEL CATTLE
EP1502602A3 (en) Methods for therapeutic vaccination
AR031370A1 (en) DOUBLE MUTANT CEPA OF BRUCELLA ABORTUS, PROCESS FOR THEIR PREPARATION, VACCINE, KIT FOR IMMUNIZATION AGAINST BRUCELLOSIS AND DIFFERENTIATION BETWEEN VACCINATED AND INFECTED ANIMALS, AND USE OF THE CEPA FOR THE PREPARATION OF A VACCINE TO PREVENT BRUCELOSIS

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000216

Kind code of ref document: A1

Effective date: 20000216

FA2A Application withdrawn

Effective date: 20031120